Status: Recruiting
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
The goal of this clinical trial is to evaluate the efficacy and safety of XTR006 injection PET visual reading in detecting brain neurofibrillary tangles (NFTs) in elderly subjects with Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), and cognitively normal individuals. The main question it aims to answer is: • What is the sensitivity and specificity of XTR006 PET visual reading results compared to the truth standard across MCI, AD, and cognitively normal subjects? Participants will: * Receive XTR006 injection * Undergo PET/CT scanning
Participants needed: 354
Trial details
Phase: Phase 3Age: 50+Biological sex: AllType: InterventionalSponsor: Sinotau Pharmaceutical GroupUpdated: Aug 11, 2025Locations: 1
Eligibility criteria
Male or female subjects aged ≥50 years. [+6]
Diagnosis of atypical AD, frontotemporal lobar degeneration (FTLD), Lewy body de... [+6]